Small amounts (1 standard drink) with food are generally safe for most patients, but risks include hypoglycaemia, delayed absorption (leading to over-drinking), dehydration, and increased pancreatitis risk
What vial strengths are available for Retatrutide
So there is a possibility there
The key shift we need The question is no longer: Can patients stop GLP-1s without regaining weight? It is: Which patients can taper, how slowly, with what lifestyle support, and with what monitoring? Until trials are designed to study deprescribing strategies, weight regain after abrupt withdrawal should not be framed as inevitability
This result was considered a statistically positive investigation, however the results did not reach the threshold to constitute a clinically meaningful study. When interpreting studies, both clinicians and scientists will opine as to whether the outcome of this study was clinically meaningful